Obviously another company that is exploring the
vascular targeting track. Did you guys notice btw that
OXGN got FTA the other day with the first vascular
targeting agent to get that? Big validation to this
tech imo. This is great overview of whole tech:

http://www.meniscus.com/horizons/3-2.pdf

--- altman23 <no_reply@yahoogroups.com> skrev: > Sent
by Cliff (he was having trouble posting) -
> thanks!
>
>
**********************************************************************
>
>
> Israeli biopharmaceutical start-up, Vascular
> Biogenics Ltd., has
> developed a new genetic treatment, GT-111, which can
> cut off the
> oxygen supply to cancerous tumors causing them to
> shrink
> dramatically, or even disappear completely, without
> any negative side-
> effects to the patient.
>
> The treatment is based on a genetic charge that
> destroys the
> endothelial cells that build the blood vessels and
> supply oxygen to a
> cancerous tumor and its metastases. Without oxygen
> the tumor begins
> to shrink in size. Unlike current treatments that
> are based on
> killing the tumor's cells through chemotherapy,
> radiation and hormone
> treatments, and cause severe side effect, VBL's
> treatment has no side
> effects because it is not targeted at carcinogenic
> cells, but at the
> blood vessels that allow the metastases to grow. The
> treatment has
> already been tested successfully in animals and is
> likely to start
> clinical trials by the end of this year.
>
> http://www.cgp.be/biotech/biotech2e.html
>
>
> ------------------------ Yahoo! Groups Sponsor
>
> To unsubscribe from this group, send an email to:
>
experimentalandunconventional-unsubscribe@yahoogroups.com
>
>
>
> Your use of Yahoo! Groups is subject to
> http://docs.yahoo.com/info/terms/
>
>

_____________________________________________________
Gå före i kön och få din sajt värderad på nolltid med Yahoo! Express
Se mer på: http://se.docs.yahoo.com/info/express/help/index.html